Close

Acceleron Pharma (XLRN) Receives FDA Orphan Drug Designation for ACE-083 in Charcot-Marie-Tooth Disease

March 5, 2019 7:07 AM EST Send to a Friend
Acceleron Pharma Inc. (NASDAQ: XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login